$SRPT Sarepta price target lowered to $140 from $240 at Piper Sandler Keeps Overweight rating on the stock and believes that the after-hours pullback in Sarepta shares is overdone. Dyne Therapeutics $DYN potential beneficiary of Sarepta's SRP-9001 miss, says Piper
  • 5
@Zonic you grab some of this in AH? I scooped 1k at 79. Thinking it’s overdone given the hype around Gene therapy, that they have so much more in the pipeline and because the data wasn’t that bad. I could be missing the significance of this data though
  • 3